Imidazoloisoquinolines

Details Imidazoloisoquinolines Imidazoloisoquinolines

2001-05-29

2003-03-04

Huang, Evelyn Mei (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S086000, C546S087000, C544S234000, C544S333000, C544S405000, C514S292000, C514S248000, C514S255050, C514S256000

Reexamination Certificate

active

06528649

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to imdazoloisoquinolines and more specifically to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA
A
receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases.
2. Description of the Related Art
The GABA
A
receptor superfamily represents one of the classes of receptors through which the major inhibitory neurotransmitter, &ggr;-aminobutyric acid, or GABA, acts. Widely, although unequally, distributed through the mammalian brain, GABA mediates many of its actions through a complex of proteins called the GABA
A
receptor, which causes alteration in chloride conductance and membrane polarization.
A number of cDNAs for GABA
A
receptor subunits have been characterized. To date at least 6&agr;, 3&bgr;, 3&ggr;, 1&egr;, 1&dgr; and 2&rgr; subunits have been identified. It is generally accepted that native GABA
A
receptors are typically composed of 2&agr;, 2&bgr;, and 1&ggr; subunits (Pritchett & Seeburg
Science
1989; 245:1389-1392 and Knight et. al.,
Recept. Channels
1998; 6:1-18). Evidence such as message distribution, genome localization and biochemical study results suggest that the major naturally occurring receptor combinations are &agr;
1
&bgr;
2
&ggr;
2
, &agr;
2
&bgr;
3
&ggr;
2
, &agr;
3
&bgr;
3
&ggr;
2
, and &agr;
5
&bgr;
3
&ggr;
2
(Mohler et. al. Neuroch. Res. 1995; 20(5): 631-636).
Benzodiazepines exert their pharmacological actions by interacting with the benzodiazepine binding sites associated with the GABA
A
receptor. In addition to the benzodiazepine site, the GABA
A
receptor contains sites of interaction for several other classes of drugs. These include a steroid binding site, a picrotoxin site, and the barbiturate site. The benzodiazepine site of the GABA
A
receptor is a distinct site on the receptor complex that does not overlap with the site of interaction for GABA or for other classes of drugs that bind to the receptor (see, e.g., Cooper, et al., The Biochemical Basis of Neuropharmacology, 6
th
ed., 1991, pp. 145-148, Oxford University Press, New York). Early electrophysiological studies indicated that a major action of the benzodiazepines was enhancement of GABAergic inhibition. Compounds that selectively bind to the benzodiazepine site and enhance the ability of GABA to open GABA
A
receptor channels are agonists of GABA receptors. Other compounds that interact with the same site but negatively modulate the action of GABA are called inverse agonists. Compounds belonging to a third class bind selectively to the benzodiazepine site and yet have little or no effect on GABA activity, but can block the action of GABA
A
receptor agonists or inverse agonists that act at this site. These compounds are referred to as antagonists.
The important allosteric modulatory effects of drugs acting at the benzodiazepine site were recognized early and the distribution of activities at different receptor subtypes has been an area of intense pharmacological discovery. Agonists that act at the benzodiazepine site are known to exhibit anxiolytic, sedative, and hypnotic effects, while compounds that act as inverse agonists at this site elicit anxiogenic, cognition enhancing, and proconvulsant effects. While benzodiazepines have a long history of pharmaceutical use as anxiolytics, these compounds often exhibit a number of unwanted side effects. These may include cognitive impairment, sedation, ataxia, potentiation of ethanol effects, and a tendency for tolerance and drug dependence.
GABA
A
selective ligands may also act to potentiate the effects of certain other CNS active compounds. For example, there is evidence that selective serotonin reuptake inhibitors (SSRIs) may show greater antidepressant activity when used in combination with GABA
A
selective ligands than when used alone.
SUMMARY OF THE INVENTION
Disclosed are certain novel compounds, particularly imidazoloisoquinolines that bind to cell surface receptors. Preferred compounds of the invention bind to GABA receptors, in particular these compounds possess affinity for the benzodiazepine site of GABA
A
receptors, including human GABA
A
receptors. Also preferred are compounds that exhibit high selectivity to the benzodiazepine site of the GABA
A
receptor. These compounds are therefore considered to be of potential use in the treatment of a broad array of diseases or disorders in patients, which are characterized by modulation of GABA
A
receptors.
Such diseases or disorders include, but are not limited to depression, anxiety, sleep disorders, cognitive disorders, low alertness, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, Down's syndrome, and benzodiazepine overdoses.
Thus, the invention provides compounds of Formula I (shown below), and pharmaceutical compositions comprising compounds of Formula I.
The invention further comprises methods of treating patients suffering from certain CNS disorders with a therapeutically effective amount of a compound of the invention. The patient may be a human or other mammal. Treatment of humans, domesticated companion animals (pet) or livestock animals suffering from certain CNS disorders with a therapeutically effective amount of a compound of the invention is encompassed by the invention.
In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds. This method comprises administering a therapeutically effective amount of a compound of the invention with another CNS active compound.
Additionally this invention relates to the use of the compounds of the invention as probes for the localization of GABA
A
receptors in tissue sections.
Accordingly, a broad aspect of the invention is directed to compounds of Formula I:
and the pharmaceutically acceptable salts, prodrug, or solvate thereof, wherein n, R
1
, R
2
, R
3
, W, Q, and X are defined below.
In another aspect, the invention provides intermediates useful for preparing the compounds of Formula I.
In a further aspect, the invention provides methods for making compounds of Formula I.
DETAILED DESCRIPTION OF THE INVENTION
The invention is directed to compounds and pharmaceutically acceptable salts, prodrugs, and solvates of compounds of Formula I (shown above) wherein
n is 1, 2, 3, or 4,
R
1
, R
2
, and R
3
are the same or different and represent:
i) hydrogen, halogen, hydroxy,
ii) R
a
wherein R
a
is
—O(C
1-8
alkyl), —NO
2
, —CN, —SO
2
NH
2
, —SO
2
NH(C
1-8
alkyl), —SO
2
N(C
1-8
alkyl) (C
1-8
alkyl), amino, —NH(C
1-8
alkyl), —N(C
1-8
alkyl)(C
1-8
alkyl), —NHCO(C
1-8
alkyl),
—N(C
1-8
alkyl)CO(C
1-8
alkyl), —NHCO
2
(C
1-8
alkyl), —N(C
1-8
alkyl)CO
2
(C
1-8
alkyl), —NHSO
2
(C
1-8
alkyl), —CONH
2
, —CONH(C
1-8
alkyl), —CON(C
1-8
alkyl) (C
1-8
alkyl), —CO
2
(C
1-8
alkyl), —S(C
1-8
alkyl), —SO(C
1-8
alkyl), or —SO
2
(C
1-8
alkyl),
wherein each C
1-8
alkyl independently is straight, branched or cyclic, contains zero, one or two double or triple bonds, and is optionally substituted with one or more of hydroxy, oxo, halogen, amino, or C
1-8
alkoxy,
or R
a
is C
1-8
alkyl, which is straight, branched or cyclic, contains zero, one or two double or triple bonds, and is unsubstituted or substituted with one or more of
a) hydroxy, b) oxo, c) halogen, e) —O(C
1-8
alkyl),
f) —NR
4
R
5
wherein
R
4
and R
5
are independently selected from hydrogen and C
1-8
alkyl, or
R
4
and R
5
may be joined together to form a monocyclic or bicyclic ring, each of which may contain one or more double bonds, or one or more of oxo, O, S, SO, SO
2
or N—R
6
,
wherein R
6
is hydrogen, C
1-6
alkyl, C
1-6
alkyl-Ar
2
, wherein Ar
2
is attached to C
1-6
alkyl at any position and is optionally substituted with one or two groups, R
b
and R
c
, wherein R
b
and R
c
independently carry the definition of R
a
, or
g) —CONR
7
R
8
, or —CO
2
R
7
wher

Affiliated with

Also associated with

Rating

Imidazoloisoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazoloisoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazoloisoquinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3006203